Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Net Income: 2020-2025

Historic Net Income for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to -$74.0 million.

  • Relay Therapeutics' Net Income rose 16.02% to -$74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.8 million, marking a year-over-year increase of 14.03%. This contributed to the annual value of -$337.7 million for FY2024, which is 1.24% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Net Income is -$74.0 million, which was down 6.08% from -$69.7 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Net Income registered a high of -$42.2 million during Q1 2021, and its lowest value of -$193.4 million during Q2 2021.
  • In the last 3 years, Relay Therapeutics' Net Income had a median value of -$81.4 million in 2024 and averaged -$81.9 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 677.14% in 2021, then skyrocketed by 60.29% in 2022.
  • Quarterly analysis of 5 years shows Relay Therapeutics' Net Income stood at -$67.5 million in 2021, then declined by 0.03% to -$67.5 million in 2022, then declined by 23.74% to -$83.5 million in 2023, then grew by 8.97% to -$76.0 million in 2024, then rose by 16.02% to -$74.0 million in 2025.
  • Its Net Income stands at -$74.0 million for Q3 2025, versus -$69.7 million for Q2 2025 and -$77.1 million for Q1 2025.